Wingspire Capital provided a $40 million senior secured credit facility to Theragenics, a developer and manufacturer of medical devices. The transaction included a $20 million revolving line of credit and a $20 million term loan. Theragenics used the proceeds of the facility to refinance existing debt and fund ongoing working capital and general corporate needs.
Now in its 40th year in business, Theragenics is a manufacturer and seller of brachytherapy “seeds” to treat prostate and other cancers. The Buford, GA-based company has also expanded into the manufacture and sale of products for interventional radiology, interventional cardiology, vascular surgery and wound closure. Theragenics’ product development capabilities focus on oncology and interventional markets.
“Wingspire Capital worked closely with the leadership team at Theragenics to understand their debt structure, working capital and corporate finance goals, and we created a senior secured credit facility that meets their exact needs,” David Wisen, founder and CEO of Wingspire Capital, said.
“Wingspire developed an understanding of our business, and provided a customized credit facility designed to support our strategic goals and objectives,” Frank Tarallo, CEO of Theragenics, said. “Wingspire is an important strategic partner for Theragenics as we look forward to our future growth.”
